Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

To understand the class of drugs known as biosimilars, it is first necessary to understand the class of drugs described as biologics. Traditionally, biologics were derived through natural ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US. From today, the medicine is commercially available to patients ...